Maider Astorkia
Research Subjects
Maider Astorkia has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Alana Nguyen
New York-Presbyterian Hospital 1 Division of Hematology and Medical Oncology, Weill Cornell Medical College New York, NewYork
30 shared publications - Alessio Pigazzi
University of California, Irvine, Orange, CA
30 shared publications - Allyson Ocean
New York-Presbyterian Hospital 1 Division of Hematology and Medical Oncology, Weill Cornell Medical College New York, NewYork
30 shared publications - Casey Owens
New York-Presbyterian Hospital 1 Division of Hematology and Medical Oncology, Weill Cornell Medical College New York, NewYork
30 shared publications - Despina Siolas
Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY
30 shared publications - Doron Betel
Applied Bioinformatics Core, Weill Cornell Medicine, New York, USA
30 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Multiplex immunofluorescence images of a tumor bed in a responding patient (A low power; B high power) and the tumor of a nonresponding patient (C low power; D high power). Pathologic response is associated with a dense and diverse immune infiltrate, consistent with the activation of antitumor immunity following BOT/BAL.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Multiplex immunofluorescence images of a tumor bed in a responding patient (A low power; B high power) and the tumor of a nonresponding patient (C low power; D high power). Pathologic response is associated with a dense and diverse immune infiltrate, consistent with the activation of antitumor immunity following BOT/BAL.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Density of immune infiltrate (A) in matched baseline vs. resection paired specimens and in the (B) resection specimens of responders and nonresponders. A, The density of Tregs is numerically reduced in the resection specimen compared with baseline, whereas CD8 T-cell density is increased. B, The density of immune cells in responders is significantly higher than that in nonresponders (3.1 cells/μm vs. 0.52 cells/μm; P = 0.0048), dominated by an infiltrate of B cells and CD8+ T cells. Pathologic treatment effect (0%–100%) is indicated. In A and B: *, dMMR colorectal cancer.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Density of immune infiltrate (A) in matched baseline vs. resection paired specimens and in the (B) resection specimens of responders and nonresponders. A, The density of Tregs is numerically reduced in the resection specimen compared with baseline, whereas CD8 T-cell density is increased. B, The density of immune cells in responders is significantly higher than that in nonresponders (3.1 cells/μm vs. 0.52 cells/μm; P = 0.0048), dominated by an infiltrate of B cells and CD8+ T cells. Pathologic treatment effect (0%–100%) is indicated. In A and B: *, dMMR colorectal cancer.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Composition of the immune infiltrate from baseline to resection, in both responding and nonresponding tumors. The proportion of Tregs decreased following BOT/BAL therapy, whereas CD8+ T cells increased. This results in a numerical increase in the CD8+ T-cell/Treg ratio, more in the responders than in the nonresponders. Log-rank P value comparing the CD8+ T-cell/Treg ratio per condition. *, dMMR colorectal cancer.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Composition of the immune infiltrate from baseline to resection, in both responding and nonresponding tumors. The proportion of Tregs decreased following BOT/BAL therapy, whereas CD8+ T cells increased. This results in a numerical increase in the CD8+ T-cell/Treg ratio, more in the responders than in the nonresponders. Log-rank P value comparing the CD8+ T-cell/Treg ratio per condition. *, dMMR colorectal cancer.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
The immune cell community is distinct in responding (n = 7) vs. nonresponding (n = 4) tumors. The pie chart identifies the prevalence of cells within 50 microns of the cell type of interest. At baseline, the microenvironment of immune cells of interest (CD8+ T cells, Tregs, and B cells) is predominantly composed of lymphatic endothelium, stromal cells, and undefined T cells. Conversely, these immune cells are notably infrequently found co-localizing with other B cells, CD4+ T cells, or CD8+ T cells. In nonresponding patients, the microenvironment of the immune cells of interest is largely composed of stromal and smooth muscle cells, accompanied by a notable increase in M2 macrophages. We also observe that the local microenvironment of plasma cells is mostly comprised of M2 macrophages. In contrast, responding patients are characterized by a markedly different immune cell microenvironment composition, with relative enrichment for B cells, T cells (CD4+, CD8+, and other undefined subtypes), and Tregs (accounting for >50% of cells within these localized regions).
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
The immune cell community is distinct in responding (n = 7) vs. nonresponding (n = 4) tumors. The pie chart identifies the prevalence of cells within 50 microns of the cell type of interest. At baseline, the microenvironment of immune cells of interest (CD8+ T cells, Tregs, and B cells) is predominantly composed of lymphatic endothelium, stromal cells, and undefined T cells. Conversely, these immune cells are notably infrequently found co-localizing with other B cells, CD4+ T cells, or CD8+ T cells. In nonresponding patients, the microenvironment of the immune cells of interest is largely composed of stromal and smooth muscle cells, accompanied by a notable increase in M2 macrophages. We also observe that the local microenvironment of plasma cells is mostly comprised of M2 macrophages. In contrast, responding patients are characterized by a markedly different immune cell microenvironment composition, with relative enrichment for B cells, T cells (CD4+, CD8+, and other undefined subtypes), and Tregs (accounting for >50% of cells within these localized regions).
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Immune infiltrate composition and neighborhood analysis in dMMR vs pMMR responding tumors.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Immune infiltrate composition and neighborhood analysis in dMMR vs pMMR responding tumors.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Density of key immune cell subsets at baseline and matched resection specimens in pMMR tumors only.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Density of key immune cell subsets at baseline and matched resection specimens in pMMR tumors only.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Density of key immune cell subsets in responders and non-responders in pMMR tumors. The pathologic response is indicated.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Density of key immune cell subsets in responders and non-responders in pMMR tumors. The pathologic response is indicated.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Distances of immune cells of interest in responders and non-responders in pMMR cases only.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from Neoadjuvant Botensilimab/Balstilimab for Localized Mismatch Repair–Proficient and –Deficient Colon Cancer: Results of the NEST Phase II Clinical Trial
Distances of immune cells of interest in responders and non-responders in pMMR cases only.